CJC-1295 vs ipamorelin: two receptors, one stack, no established benefit

Why this pair exists

These two are sold together so routinely that the combination has picked up its own shorthand. "cjcipa" appears as an alias on our own CJC-1295 profile, which tells you how established the pairing is in the market.

The rationale is real, and it starts with the receptors.

Ratings from our research directory. Prices from our price market, checked 25 July 2026.

Your body has two separate switches for growth hormone release, and each compound presses a different one. Pressing both is the whole idea behind the stack.

That's a mechanistic rationale, not a trial result. It's a reasonable thing to hypothesise, and hypothesising is where it currently stops.

Both raise growth hormone. That's the trap.

Here's what makes this pair genuinely tricky to think about clearly.

Both compounds do what they claim at the level of hormones. CJC-1295 produces prolonged increases in growth hormone and IGF-1. Ipamorelin stimulates GH release through the ghrelin receptor. Neither of those is in dispute.

So a stack that raises GH more than either compound alone is a plausible, and probably measurable, outcome.

Now the part that gets skipped: nobody has established that raising growth hormone this way produces the results people want.

Our CJC-1295 profile is explicit that the trials did not establish clinical benefit for fat loss, muscle gain, recovery, sleep, or longevity. For ipamorelin, early volunteer studies establish pharmacology rather than wellness benefit.

That list covers essentially every reason anyone buys either compound.

GH and IGF-1 are surrogate markers. They stand in for outcomes because they're easy to measure and plausibly connected. Sometimes a surrogate holds; often it doesn't, and the history of medicine is full of interventions that moved a marker beautifully and changed nothing that mattered.

Stacking two compounds that each move a surrogate gets you more surrogate movement. It doesn't convert a marker into an outcome. We go through this properly in why evidence maturity beats online momentum.

The asymmetry worth knowing

If you're going to compare them on evidence, the comparison runs opposite to what most people assume.

Ipamorelin has the stronger human evidence. It reached a randomized phase 2 trial in postoperative ileus.²

And that evidence is negative. No statistically significant improvement in key or secondary efficacy endpoints.

CJC-1295 has no comparable outcome trial at all. Its evidence is small healthy-volunteer studies measuring hormone levels.

So one compound was properly tested for something and missed, while the other hasn't been properly tested for anything. Neither position supports the marketing, and the second is weaker even though it looks cleaner.

A compound with no failed trials isn't a compound that works. It's often just a compound nobody has tested.

Full detail in what ipamorelin is and what CJC-1295 is.

Check which CJC-1295 you're buying

One practical warning specific to this pair.

"CJC-1295" names two different molecules, with DAC and without, and the without-DAC version is also sold as Mod GRF 1-29. They differ in how long they stay active.

In our price market, CJC-1295 (without DAC) and Mod GRF 1-29 appear as separate rows carrying identical price ranges and identical vendor counts, which is what one compound listed under two names looks like.

Ipamorelin has no equivalent ambiguity. If a stack listing just says "CJC-1295," that's worth resolving before anything else.

What the supply looks like

Between them, these two are covered by four published lab records in our testing ledger.³

One for CJC-1295 with DAC: a 5mg vial measuring 5.19mg at 99.288% purity. Three for ipamorelin, two of them tight and one 20.4% over on a 5mg vial.

Four records against 27 vendor listings.

The dose accuracy in those four is better than the GLP-1 side of our ledger, where overfill runs to a median of +13.1%. That's a small comfort drawn from a very small sample, and it shouldn't be read as a pattern.

Where the comparison lands

The stack rationale is mechanistically sensible. Two receptors, two switches, plausibly additive.

Both raise growth hormone. That part is established.

Neither has established clinical benefit for fat loss, muscle, recovery, sleep, or longevity, which is the entire marketing surface.

The better-evidenced one missed its endpoints.

So the honest comparison isn't which to choose. It's that both sit at the same place: real pharmacology, no established outcomes, and a supply documented by four certificates.¹

Profiles with graded outcomes and sources: CJC-1295 and ipamorelin.